{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-067670","form_type":"8-K","ticker":"TXMD","cik":"0000025743","company_name":"TherapeuticsMD, Inc.","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.447855+00:00","generated_at":"2026-05-31T10:11:28.571773+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"TherapeuticsMD Q2 net loss narrows to $1.05M; evaluating strategic alternatives","bullets":["Net loss from continuing operations $1.05M ($0.09/sh) vs $2.4M ($0.24/sh) in Q2 2023.","License revenue from Mayne License Agreement fell 46.5% to $234K from $437K.","Operating expenses decreased 8.1% to $2.7M; cash and equivalents $5.2M as of June 30.","Company continues to evaluate strategic alternatives including M&A or asset sale; no assurance of outcome."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-067670","json":"https://secwatch.observer/filing/0001213900-24-067670.json","markdown":"https://secwatch.observer/filing/0001213900-24-067670.md","text":"https://secwatch.observer/filing/0001213900-24-067670.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/25743/000121390024067670/0001213900-24-067670-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/25743/000121390024067670/ea0211036-8k_therape.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:11:28.571773+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}